In-Pharma-tion ESR workshop
Online, 14. – 15. October 2021
InPharma consists of 11 Beneficiaries who will employ the 13 Early Stage Resarchers (ESRs) uniting world-leading academic research groups and pharma companies on their common search for better drug formulation processes which lead to safer and more efficient drugs for patients while simultaneously eradicating animal testing from the process and reducing development costs.
Day 1: Introduction to industrial challenges and different computational tools to model formulations
Morning session on industrial challenges with a brief overview of computational modeling of formulations
9:00–9:15
Welcome address to this ESR workshop in Basel
Prof. Brendan Griffin, University College Cork & Prof. Martin Kuentz, FHNW
9:15–10:00
Introduction to challenges in pharmaceutical drug profiling
Dr. Nicole Wyttenbach, Roche Ltd.
10:00–10:45
Introduction to pharmaceutical solid state characterization
Dr. Rolf Hilfiker, Solvias Ltd.
10:45–11:00
Break
11:00–11.45
Overview of different computational approaches to study drug-excipient interactions
Prof. Martin Kuentz, FHNW
11:45–13:00
Lunch break
Afternoon session on individual tools of computational pharmaceutics
13:00–13:45
Machine learning in selected pharmaceutical applications
Prof. Markus Lill, University of Basel
13:45–14:30
COSMO-RS model to aid with selection of excipients
Dr. Daniel Price, Merck KGaA
14:30–14:45
Break
14:45–15:30
Molecular dynamics simulations in pharmaceutical material science
Dr. Jacob Gavartin, Schrödinger Inc.
15:30–16:15
Opportunities of in silico property prediction
Dr. Jon Christensen, Hafnium Labs
16:15–16:45
Wrap-up and discussion
All participants
Day 2 : Introduction to biopharmaceutical challenges and physiologically-based pharmacokinetic (PBPK) modeling in pharmaceutics
Morning session on biopharmaceutical challenges and an overview of PBPK tools
9:00–9:45
Challenges of oral delivery and from BCS to rDCS
Prof. Jennifer Dressman, Fraunhofer Institute Frankfurt
9:45–10:30
Challenges in special patient populations
Prof. Maria Vertzoni, National and Kapodistrian University of Athens
10:30–10:45
Break
10:45–11:30
Physiologically-based absorption modeling
Dr. André Dallman, Bayer AG
11:30–13:00
Lunch break
Afternoon session on PBPK modeling applications
13:00–13:45
The Simcyp- approach to absorption modeling
Dr. David B. Turner, Certara
13:45–14:30
Industrial case studies of using PBPK modeling
Dr. Xavier Pepin, Astra Zeneca
14:30–15:15
PBPK modeling in a regulatory environment
Dr. Paul Seo, FDA
15:15–16:00
Wrap-up and discussion
All participants
Main contacts
Prof. Martin Kuentz, FHNW
Main organiser
Prof. Brendan Griffin, University College Cork
InPharma Coordinator